2018
DOI: 10.1016/j.ijcard.2018.03.098
|View full text |Cite
|
Sign up to set email alerts
|

Identifying novel phenotypes of acute heart failure using cluster analysis of clinical variables

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
46
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 62 publications
(47 citation statements)
references
References 46 publications
1
46
0
Order By: Relevance
“…These patients were least often treated with neurohormonal therapies (beta blockers, ACE-Inhibitors) and implanted device therapies (ICD, cardiac resynchronization therapy-defibrillator). Horiuchi et al(11) studied a smaller population of 345 consecutively admitted patients with acute heart failure hospitalized in the cardiovascular intensive care unit, with similar findings.In brief, the previous studies (7-11) subclassified their patient populations into smaller phenotypically distinct groups with unique clinical trajectories in terms of outcomes and response to various treatments. Direct comparison with our results is difficult due to the differences in initial patient population, the variables available and used for clustering, the distinguishing variables that define each phenogroup, and the variation in outcome measures used to risk-stratify phenogroups and report survival analysis.…”
mentioning
confidence: 64%
See 2 more Smart Citations
“…These patients were least often treated with neurohormonal therapies (beta blockers, ACE-Inhibitors) and implanted device therapies (ICD, cardiac resynchronization therapy-defibrillator). Horiuchi et al(11) studied a smaller population of 345 consecutively admitted patients with acute heart failure hospitalized in the cardiovascular intensive care unit, with similar findings.In brief, the previous studies (7-11) subclassified their patient populations into smaller phenotypically distinct groups with unique clinical trajectories in terms of outcomes and response to various treatments. Direct comparison with our results is difficult due to the differences in initial patient population, the variables available and used for clustering, the distinguishing variables that define each phenogroup, and the variation in outcome measures used to risk-stratify phenogroups and report survival analysis.…”
mentioning
confidence: 64%
“…Other investigators have used machine learning or cluster analysis to identify subgroups of patients with distinct phenotypes that differ in their risk profiles and survival outcomes (7)(8)(9)(10)(11). These researchers have studied heterogeneous populations of patients with primary HTN and the absence of HF (9), HFpEF alone (7,8), and mixed populations of HFrEF and HFpEF combined (10,11). However, to our knowledge, ours is the first study to use hierarchical clustering to identify subgroups of patients with subclinical diastolic dysfunction.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Other investigators have used machine learning or cluster analysis to identify subgroups of patients with distinct phenotypes that differ in their risk profiles and survival outcomes (7-11). These researchers have studied heterogeneous populations of patients with primary HTN and the absence of HF (9), HFpEF alone (7,8), and mixed populations of HFrEF and HFpEF combined (10,11). However, to our knowledge, ours is the first study to use hierarchical clustering to identify subgroups of patients with subclinical diastolic dysfunction.…”
Section: Discussionmentioning
confidence: 99%
“…Due to the complexity of the data and heterogeneity of patients in medicine, intuitively identifying groups with similar phenotypes can be difficult and therefore the ability to identify these groups using machine learning methods may allow for more targeted diagnostics, therapeutic strategies and prognostication. For example, unsupervised machine learning has been previously used in research to divide large heterogeneous populations of patients into smaller unique phenogroups, including patients with HFpEF (7,8), patients with primary hypertension (HTN) without heart failure (9), and mixed patient groups with HFrEF and HFpEF combined (10,11).…”
Section: Introductionmentioning
confidence: 99%